![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Antiviral Response and Resistance Analysis of Treatment-Naïve HCV Infected Subjects Receiving Single and Multiple Doses of GS-9190
|
|
|
Reported by Jules Levin
AASLD 2010 Nov 2 Boston
J Harris1, A Bae1, S Sun2, E Svarovskaia2, M Miller2, and H Mo2
1Gilead Sciences, Inc, Durham, NC, USA; 2Gilead Sciences, Inc, Foster City, USA
![](../images/110710/110710-2/con-1.gif)
![](../images/110710/110710-2/summ-2.gif)
![](../images/110710/110710-2/back-3.gif)
![](../images/110710/110710-2/obj-4.gif)
![](../images/110710/110710-2/HCV-5.gif)
![](../images/110710/110710-2/NN5B-6.gif)
![](../images/110710/110710-2/ABC-7.gif)
![](../images/110710/110710-2/DOSE-8.gif)
![](../images/110710/110710-2/lowLev-9.gif)
![](../images/110710/110710-2/AS-10.gif)
![](../images/110710/110710-2/Follow-11.gif)
![](../images/110710/110710-2/C-12.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|